Visit Our Booth #801 to Learn How Our Products Can Help Achieve Better Patient Outcomes

BioTissue provides premium regenerative therapies for optimum outcomes in ocular surface disease. BioTissue’s proprietary cryopreserved amniotic membrane, used in both the Prokera® and AmnioGraft® family of products, is the only amniotic membrane FDA-designated as anti-inflammatory, anti-scarring, and anti-angiogenic.

The Right Healing. The Right Product.

We are in a race against time to heal chronic wounds. BioTissue products provide the natural healing properties of human birth tissue to the wound. The BioTissue proprietary CryoTek cryopreservation process is the only tissue processing method shown to produce an allograft comparable to the native tissue.1-2

Brand Launch Celebration

We Are BioTissue

Technology moves fast. Stay ahead of the curve and join us for an exciting night to celebrate with the innovators of regenerative medicine in the field of ophthalmology.

Downloadable Resources

  • To access downloadable resources, kindly fill out the form below.
  • By clicking the button below, I agree to receive marketing communications from BioTissue. I am aware that I can unsubscribe at any time.
  • This field is for validation purposes and should be left unchanged.
Tan EK, Cooke M, Mandrycky C, et al. Structural and biological comparison of cryopreserved and fresh amniotic membrane tissues. J Biomater Tissue Eng. 2014;(4):379–388.
Cooke M, Tan EK, Mandrycky C, et al. Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. J Wound Care. 2014;23(10):4 65-476.
Solomon A, Pires RTF and Tseng SCG. Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia. Ophthalmology. 2001; 108: 449-60
Kheirkhah A, Casas V, Esquenazi S, et al. New surgical approach for superior conjunctivochalasis. Cornea. 2007;26(6):685-691.
Kheirkhah A, Casas V, Blanco G, Li W, Hayashida Y, Chen YT, Tseng SC. Amniotic membrane transplantation with fibrin glue for conjunctivochalasis. Am J Ophthalmol. 2007;144(2):311-3.
Shay E, He H, Sakurai S, Tseng SC. Inhibition of angiogenesis by HC·HA, a complex of hyaluronan and the heavy chain of inter-inhibitor, purified from human amniotic membrane. Invest Ophthalmol. Vis Sci. 2011; 52(5): 2669–2678.
Sheha H, Tello C, Al-Aswad L, Sayed M, Lee R. Outcomes of the Shunt Tube Exposure Prevention Study (STEPS), a randomized clinical trial. Opthalmol Glaucoma. [Online] August 16, 2019.
Finger PT, Jain P, Mukkamala SK. Super-thick amniotic membrane for ocular surface reconstruction. Am J Opthalmol. 2019;198:45-53.
Slentz, D. and Nelson, C. (2019). Novel Use of Cryopreserved Ultra-thick Human Amniotic Membrane for Management of Anophthalmic Socket Contracture. Ophthalmic Plastic and Reconstructive Surgery, 35(2), pp.193-196.
Johnson, Amy, et al. “Understanding the impact of preservation methods on the integrity and functionality of placental allografts.” Annals of plastic surgery 79.2 (2017): 203-213.